0001209191-24-000138.txt : 20240102 0001209191-24-000138.hdr.sgml : 20240102 20240102164118 ACCESSION NUMBER: 0001209191-24-000138 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240102 FILED AS OF DATE: 20240102 DATE AS OF CHANGE: 20240102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Di Donato Brian CENTRAL INDEX KEY: 0001766498 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39992 FILM NUMBER: 24503085 MAIL ADDRESS: STREET 1: C/O ACHILLION PHARMACEUTICALS, INC STREET 2: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Immunocore Holdings plc CENTRAL INDEX KEY: 0001671927 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 90 PARK DRIVE STREET 2: MILTON PARK, ABINGDON CITY: OXFORDSHIRE STATE: X0 ZIP: OX14 4RY BUSINESS PHONE: 01235 5430281 MAIL ADDRESS: STREET 1: 90 PARK DRIVE STREET 2: MILTON PARK, ABINGDON CITY: OXFORDSHIRE STATE: X0 ZIP: OX14 4RY FORMER COMPANY: FORMER CONFORMED NAME: Immunocore Ltd DATE OF NAME CHANGE: 20160412 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2024-01-02 0 0001671927 Immunocore Holdings plc IMCR 0001766498 Di Donato Brian C/O IMMUNOCORE HOLDINGS PLC 92 PARK DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RY UNITED KINGDOM 0 1 0 0 Chief Financial Officer Ordinary Shares 19230 D Employee Share Option (Right to Buy) 17.46 2030-06-30 Ordinary Shares 56250 D Employee Share Option (Right to Buy) 26.00 2031-02-03 Ordinary Shares 127152 D Employee Share Option (Right to Buy) 24.66 2032-02-15 Ordinary Shares 67977 D Employee Share Option (Right to Buy) 64.53 2033-02-15 Ordinary Shares 67949 D The original option award was for 300,000 shares. 25% of the shares subject to the option award vested on July 1, 2021, and 6.25% of the shares subject to the option award vested or shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. The original option award was for 406,884 shares. 25% of the shares subject to the option award vested on February 4, 2022, and 6.25% of the shares subject to the option award vested or shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. The original option award was for 120,843 shares. 25% of the shares subject to the option award vested on February 16, 2023, and 6.25% of the shares subject to the option award vested or shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. 25% of the shares subject to the option award shall vest on February 16, 2024, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Exhibit List - Exhibit 24 - Power of Attorney /s/ Brian Di Donato 2024-01-02 EX-24 2 poa.txt POA DOCUMENT Exhibit 24 POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents, that the undersigned hereby constitutes and appoints each of Divakar Gupta, Courtney Thorne, Norman Reilly III, Wouter Deleersnyder, Catherine Rude and Jason Minio of Cooley LLP, and Brian Di Donato and Lily Hepworth of Immunocore Holdings plc (the "Company"), signing individually, the undersigned's true and lawful attorneys-in-fact and agents to: (1) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC") a Form ID, Uniform Application for Access Codes to File on EDGAR, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any rule or regulation thereunder; (2) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the SEC Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 16(a) of the Exchange Act and the rules thereunder in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company; (3) Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Form ID and Forms 3, 4 or 5 (including amendments thereto and joint filing agreements in connection therewith) and file such forms with the SEC and any stock exchange, self-regulatory association or any similar authority; and (4) Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Form ID or Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or employed by or a partner at Cooley LLP, as applicable. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below. Date: November 17, 2023 /s/ Brian Di Donato Name: Brian Di Donato